Current Opinion in Investigational Drugs | Most viewed articles in past 30 days

Log on / register
Feedback | Support | My details

home journals A-Z subject areas advanced search authors reviewers libraries jobs about my BioMed Central home journals A-Z subject areas advanced search authors reviewers libraries jobs about my BioMed Central

Quick Search

	Current Opinion in Investigational Drugs
	BioMed Central
	PubMed Central
	PubMed

Jump to article


vol.	page no.

Current Opinion in Investigational Drugs

Most viewed

Current Opinion in Investigational Drugs: Most viewed articles in past 30 days

[more info]

Figures given indicate the abstract, full text and PDF accesses on BioMed Central for each article, over the last 30 days. All research articles are also available via the PubMed Central archive, so the total number of accesses to each article is significantly higher. Lists of most-viewed articles in the past year and all time most-viewed articles are also available

most viewed articles over the last 30 days from all BioMed Central Journals

1. Accesses 55	Review Evolution of schizophrenia drugs: A focus on dopaminergic systems SS Nikam, AK Awasthi Current Opinion in Investigational Drugs 2008, 9:37-46 (7January2008) [PDF] [PubMed] [Related articles]
2. Accesses 50	Review Sirtuins: Novel targets for metabolic disease PJ Elliott, M Jirousek Current Opinion in Investigational Drugs 2008, 9:371-378 (4April2008) [PDF] [PubMed] [Related articles]
3. Accesses 50	Review Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors JA McCubrey, M Milella, A Tafuri, AM Martelli, P Lunghi, A Bonati, M Cervello, JT Lee, LS Steelman Current Opinion in Investigational Drugs 2008, 9:614-630 (28May2008) [PDF] [PubMed] [Related articles]
4. Accesses 47	Review Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and antinausea activities RM Navari Current Opinion in Investigational Drugs 2008, 9:774-785 (1July2008) [PDF] [PubMed] [Related articles]
5. Accesses 45	Review Nuclear receptors as drug targets in obesity, dyslipidemia and atherosclerosis MK Hansen, TM Connolly Current Opinion in Investigational Drugs 2008, 9:247-255 (28February2008) [PDF] [PubMed] [Related articles]
6. Accesses 39	Review Homomeric and heteromeric P2X3 receptors in peripheral sensory neurons J-D Brederson, MF Jarvis Current Opinion in Investigational Drugs 2008, 9:716-725 (1July2008) [PDF] [PubMed] [Related articles]
7. Accesses 37	Review Neuroimmune interactions and pain: Focus on glial-modulating targets EA Romero-Sandoval, RJ Horvath, JA DeLeo Current Opinion in Investigational Drugs 2008, 9:726-734 (1July2008) [PDF] [PubMed] [Related articles]
8. Accesses 35	Review ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases C Ding, J Xu, J Li Current Opinion in Investigational Drugs 2008, 9:515-522 (25April2008) [PDF] [PubMed] [Related articles]
9. Accesses 35	Review Cognitive endpoints as disease biomarkers: Optimizing the congruency of preclinical models to the clinic M Day, F Balci, HI Wan, GB Fox, JL Rutkowski, G Feuerstein Current Opinion in Investigational Drugs 2008, 9:696-706 (1July2008) [PDF] [PubMed] [Related articles]
10. Accesses 33	Review Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes CF Deacon Current Opinion in Investigational Drugs 2008, 9:402-413 (4April2008) [PDF] [PubMed] [Related articles]

Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us